Preparation & Measurement Guide

TB-500 5mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a TB-500 5mg vial.

Research use only Educational summary of a commonly documented convention. Not approved for human use.
Vial Size TB-500 5mg
Preparation 1mL bacteriostatic water
Concentration 5mg/mL after preparation
Documented Convention 500mcg-1mg once daily

1. Preparation and Measurement

TB-500 5mg With 1mL of Diluent

Add 1mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

5mg / 1mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 1mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period Documented amount Measurement
Weeks 1-2 500mcg once daily 0.1mL / 10 units
Weeks 3-4 750mcg once daily 0.15mL / 15 units
Weeks 5-8 1mg once daily 0.2mL / 20 units

Vial estimate: One 5mg vial contains approximately 10 administrations at the first listed amount or 5 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 1mL.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • TB-500 5mg vial.
  • 1mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

TB-500 is associated with thymosin beta-4 research involving cell migration, wound models, and tissue repair. Commercial TB-500 material should not be assumed identical to full-length thymosin beta-4 used in published studies.

TB-500 is not an approved therapeutic drug. No clinically validated dosing schedule has been established.

Primary Research and Regulatory References

  1. Thymosin beta-4 wound-healing research
  2. Thymosin beta-4 cell-migration study
  3. Thymosin beta-4 repair research review

Research Materials

Review TB-500 5mg Product Information

← Back to Dosage Protocols

Research-use disclaimer: TB-500 5mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.